Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non small-cell lung cancer: A phase II study

A. F. Scinto, V. Ferraresi, M. Milella, E. Tucci, C. Santomaggio, R. Pasquali-Lasagni, M. R. Del Vecchio, N. Campioni, M. Nardi, F. Cognetti

Research output: Contribution to journalArticle

Abstract

From March 1993 to February 1997, 43 eligible patients with inoperable stage IIIA (ten patients) and stage IIIB (33 patients), histologically confirmed NSCLC received 3 courses of the ICE combination (ifosfamide 1.5 g m-2 and mesna 750 mg m-2 two times a day, cisplatin 25 mg m-2 and etoposide 100 mg m-2, all administered intravenously (i.v.) on days 1-3 every 3 weeks) with G-CSF support. After three cycles, patients were submitted to radical surgery or received two additional courses of the ICE regimen and/or curative radiotherapy. Grade 3-4 neutropenia occurred in 21% of 114 evaluable courses, but was of short duration, leading to neutropenic fever in 5% of the courses. Severe thrombocytopenia and anaemia were observed in 13% and 3% of the courses respectively. Non-haematological toxicity was generally mild with only two episodes of reversible renal impairment. The overall response rate after three chemotherapy courses was 69% (28 partial responses, one complete response). Ten patients (8/10 patients in stage IIIA, 2/33 patients in stage IIIB) underwent radical surgery. Median TTP for patients not undergoing surgery (n = 33) was 8 months (range 3-34+); median DFS for patients rendered NED by surgery (n = 10) was 25 months (range 1-54+). Median OS for the entire group was 12.5 months (range 2-57+). The ICE regimen is active in locally advanced NSCLC with acceptable toxicity and warrants further exploration as induction chemotherapy in larger series.

Original languageEnglish
Pages (from-to)1031-1036
Number of pages6
JournalBritish Journal of Cancer
Volume81
Issue number6
DOIs
Publication statusPublished - 1999

Keywords

  • Chemotherapy
  • G-CSF
  • ICE
  • Inoperable
  • Locally advanced
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non small-cell lung cancer: A phase II study'. Together they form a unique fingerprint.

  • Cite this